ALN-AGT01 for Mild to Moderate Hypertension
A Study to Evaluate ALN-AGT01 RVR in Adult Patients With Mild to Moderate Hypertension Pretreated With Zilebesiran
- Age
- 18 – 75
- Sex
- Any
- Trial phase
- Phase 2
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 93 (estimated)
- Sponsor
- Alnylam Pharmaceuticals · Industry
This trial is looking for adults with mild to moderate high blood pressure. Participants will be evaluated to see how well they respond to the treatment after using another medication called zilebesiran.
You may be able to join if
- I am an adult with a systolic blood pressure between 130 and 170 mmHg
- I am not taking any antihypertensive medication or I am stable on up to 2 antihypertensive medications
- I am an adult with a systolic blood pressure between 140 and 170 mmHg
- I have stopped taking all antihypertensive medications except for a calcium channel blocker or a thiazide diuretic for at least 3 weeks
You may not be able to join if
- I have known secondary hypertension
- My potassium level is more than 5 mmol/L
- My kidney function is below an estimated glomerular filtration rate of 30 mL/min/1.73m²
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your EligibilityThe purpose of this study is to evaluate the efficacy, pharmacodynamics (PD), and safety of ALN-AGT01 RVR in participants with mild to moderate hypertension pretreated with zilebesiran.
Loading trial locations…